source
- Analysts deem AstraZeneca-BMS merger unlikely despite market buzzAnalysts say that talks between AstraZeneca and Bristol Myers Squibb are unlikely to result in a merger because the two companies have overlapping product lines that would attract heavy antitrust s…
- BioNTech appoints Sobi CEO Guido Oelkers as new chief, founders to launch separate mRNA biotechBioNTech announced that Guido Oelkers, current chief executive of Swedish Orphan Biovitrum (Sobi), will assume the role of CEO in early 2027. The move follows the earlier decision of co‑founders U…